Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry

Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry

Abstract Introduction Data assessing longer-term real-world effectiveness and treatment patterns with upadacitinib (UPA), a Janus kinase inhibitor, in rheumatoid arthritis (RA) are lacking. We assessed improvement in clinical and patient-reported outcomes and treatment patterns for up to 12 months a...

Full description

Bibliographic Details
Main Authors: Joshua F. Baker, Patrick Zueger, Mira Ali, Denise Bennett, Miao Yu, Yolanda Munoz Maldonado, Robert R. McLean
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-02-01
Series:Rheumatology and Therapy
Subjects:
Rheumatoid arthritis
Real-world evidence
Upadacitinib
Registry
Patient-reported outcomes
Online Access:https://doi.org/10.1007/s40744-024-00639-4

Internet

https://doi.org/10.1007/s40744-024-00639-4

Similar Items